Literature DB >> 30190408

Minimal functional driver gene heterogeneity among untreated metastases.

Johannes G Reiter1,2, Alvin P Makohon-Moore3, Jeffrey M Gerold2, Alexander Heyde2, Marc A Attiyeh3, Zachary A Kohutek4, Collin J Tokheim5, Alexia Brown3, Rayne M DeBlasio3, Juliana Niyazov3, Amanda Zucker3, Rachel Karchin5,6, Kenneth W Kinzler7,8,9, Christine A Iacobuzio-Donahue3,10, Bert Vogelstein7,8,9,11, Martin A Nowak12,13.   

Abstract

Metastases are responsible for the majority of cancer-related deaths. Although genomic heterogeneity within primary tumors is associated with relapse, heterogeneity among treatment-naïve metastases has not been comprehensively assessed. We analyzed sequencing data for 76 untreated metastases from 20 patients and inferred cancer phylogenies for breast, colorectal, endometrial, gastric, lung, melanoma, pancreatic, and prostate cancers. We found that within individual patients, a large majority of driver gene mutations are common to all metastases. Further analysis revealed that the driver gene mutations that were not shared by all metastases are unlikely to have functional consequences. A mathematical model of tumor evolution and metastasis formation provides an explanation for the observed driver gene homogeneity. Thus, single biopsies capture most of the functionally important mutations in metastases and therefore provide essential information for therapeutic decision-making.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Year:  2018        PMID: 30190408      PMCID: PMC6329287          DOI: 10.1126/science.aat7171

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  90 in total

Review 1.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

Review 2.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

Review 3.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

4.  State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.

Authors:  Elliot B Levy; Maria I Fiel; Stanley R Hamilton; David E Kleiner; Shannon J McCall; Peter Schirmacher; William Travis; Michael D Kuo; Robert D Suh; Alda L Tam; Shaheen U Islam; Katherine Ferry-Galow; Rebecca A Enos; James H Doroshow; Hala R Makhlouf
Journal:  J Clin Oncol       Date:  2020-03-05       Impact factor: 44.544

5.  Estimating growth patterns and driver effects in tumor evolution from individual samples.

Authors:  Leonidas Salichos; William Meyerson; Jonathan Warrell; Mark Gerstein
Journal:  Nat Commun       Date:  2020-02-05       Impact factor: 14.919

Review 6.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

7.  Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life.

Authors:  Jason A Somarelli; Amy M Boddy; Heather L Gardner; Suzanne Bartholf DeWitt; Joanne Tuohy; Kate Megquier; Maya U Sheth; Shiaowen David Hsu; Jeffrey L Thorne; Cheryl A London; William C Eward
Journal:  Mol Biol Evol       Date:  2020-01-01       Impact factor: 16.240

8.  Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Authors:  Lise Boussemart; Annie Nelson; Michael Wong; Jeffrey S Ross; Jeffrey Sosman; Janice Mehnert; Gregory Daniels; Kari Kendra; Siraj Mahamed Ali; Vincent A Miller; Alexa B Schrock
Journal:  Oncologist       Date:  2019-01-25

Review 9.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

Review 10.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.